Filters

Term Search
You can select from the dropdown list OR enter your own terms to refine the search.

Last Updated: 10/31/2025

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 169 publications

Selected drugs, therapeutic alternatives, and price benchmarks for IPAY 2027 Medicare drug price negotiation.

Selected drugs, therapeutic alternatives, and price benchmarks for IPAY 2027 Medicare drug price negotiation.

Journal: Journal of managed care & specialty pharmacy
Published: September 12, 2025

Efficacy and Safety of VMAT-2 Inhibitors and Dopamine Stabilizers for Huntington's Chorea: A Systematic Review, Meta-Analysis, and Trial Sequential Analysis.

Efficacy and Safety of VMAT-2 Inhibitors and Dopamine Stabilizers for Huntington's Chorea: A Systematic Review, Meta-Analysis, and Trial Sequential Analysis.

Journal: Medical sciences (Basel, Switzerland)
Published: August 01, 2025

A narrative review of Phase III and IV clinical trials for the pharmacological treatment of Tourette's syndrome in children, adults, and older adults.

A narrative review of Phase III and IV clinical trials for the pharmacological treatment of Tourette's syndrome in children, adults, and older adults.

Journal: Medicine
Published: June 09, 2025

Efficacy and safety of vesicular monoamine transporter 2 inhibitors for Huntington's disease chorea based on network meta-analysis.

Efficacy and safety of vesicular monoamine transporter 2 inhibitors for Huntington's disease chorea based on network meta-analysis.

Journal: Frontiers in pharmacology
Published: May 29, 2025

Real-World Experiences with VMAT2 Inhibitors in Pediatric Hyperkinetic Movement Disorders.

Real-World Experiences with VMAT2 Inhibitors in Pediatric Hyperkinetic Movement Disorders.

Journal: Tremor and other hyperkinetic movements (New York, N.Y.)
Published: April 04, 2025

Deutetrabenazine treatment outcomes with doses above U.S. Food and Drug Administration maximum approved doses in Huntington's disease chorea: A dual-site analysis.

Deutetrabenazine treatment outcomes with doses above U.S. Food and Drug Administration maximum approved doses in Huntington's disease chorea: A dual-site analysis.

Journal: Journal of Huntington's disease
Published: March 24, 2025

Cost Trends of New-To-Market Neurologic Medications: An Insurance Claims Database Analysis.

Cost Trends of New-To-Market Neurologic Medications: An Insurance Claims Database Analysis.

Journal: Neurology
Published: February 27, 2025

A narrative review of phase III and IV clinical trials for the pharmacological treatment of Huntington's disease in adults.

A narrative review of phase III and IV clinical trials for the pharmacological treatment of Huntington's disease in adults.

Journal: Medicine
Published: February 19, 2025

The Huntington's disease drug pipeline: a review of small molecules and their therapeutic targets.

The Huntington's disease drug pipeline: a review of small molecules and their therapeutic targets.

Journal: Progress in molecular biology and translational science
Published: February 13, 2025

From assessment to intervention: evidence-based approaches in tardive dyskinesia.

From assessment to intervention: evidence-based approaches in tardive dyskinesia.

Journal: CNS spectrums
Published: February 12, 2025

Valbenazine for the treatment of chorea associated with Huntington's disease.

Valbenazine for the treatment of chorea associated with Huntington's disease.

Journal: Expert opinion on pharmacotherapy
Published: December 27, 2024

Safety and Efficacy of Deutetrabenazine at High versus Lower Daily Dosages in the ARC-HD Study to Treat Chorea in Huntington Disease.

Safety and Efficacy of Deutetrabenazine at High versus Lower Daily Dosages in the ARC-HD Study to Treat Chorea in Huntington Disease.

Journal: CNS drugs
Published: November 17, 2024
Showing 1-12 of 169

Last Updated: 10/31/2025